Business Context and Reporting Period
Company: Immutep Ltd (ASX: IMM, NASDAQ: IMMP)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: Immutep is a late-stage biotechnology company developing immunotherapies targeting the LAG-3 pathway for cancer and autoimmune diseases. The company has no approved products for commercial sale and relies on clinical development, strategic collaborations, and government grants. Its lead asset is eftilagimod alpha ("efti"), currently in Phase II/III trials for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer (MBC).
Key Financial Metrics (Fiscal Year 2024)
| Metric | 2024 (A$) | 2023 (A$) |
|---|---|---|
| Total Revenue & Other Income | 7.84 million | 5.20 million |
| License Revenue | 0 | 0 |
| Grant Income (R&D Tax Incentives) | 3.72 million | 3.31 million |
| Interest Income | 3.88 million | 0.94 million |
| Research & Development Expenses | (41.55 million) | (36.26 million) |
| Corporate Administrative Expenses | (8.85 million) | (8.68 million) |
| Net Loss | (42.72 million) | (39.90 million) |
| Cash and Cash Equivalents (End of Period) | 161.79 million | 123.42 million |
| Total Assets | 201.58 million | 147.45 million |
| Total Liabilities | 12.06 million | 10.98 million |
| Net Assets (Equity) | 189.52 million | 136.47 million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately A$2.8 million (7%) to A$42.7 million, primarily driven by a A$5.3 million increase in R&D expenses due to the completion of patient recruitment for the TACTI-003 trial and active recruitment for AIPAC-003.
- Interest Income Surge: Interest income increased significantly by A$2.9 million (310%) to A$3.9 million, attributed to higher cash balances and elevated interest rates in 2024.
- Capital Raising: The company raised approximately A$100.2 million in June 2024 via an entitlement offer (A$89.6m institutional, A$10.6m retail), significantly bolstering liquidity.
- Grant Income: Grant income increased by A$0.4 million, largely due to the French Crédit d'Impôt Recherche scheme.
- Share Count: Ordinary shares outstanding increased to 1,452,612,290 as of June 30, 2024, following the capital raising and exercise of performance rights.
Guidance, Outlook, and Management Commentary
- Clinical Pipeline Progress:
- TACTI-004 (NSCLC): Preparing to commence a registrational Phase III trial in 1st line NSCLC in collaboration with Merck & Co. (MSD), which will supply KEYTRUDA at no cost. Enrollment of ~750 patients is planned for late 2024/early 2025.
- TACTI-003 (HNSCC): Completed enrollment (171 patients). Positive results were reported in July 2024 showing an Objective Response Rate (ORR) of 35.5% in PD-L1 negative patients, outperforming historical controls.
- AIPAC-003 (Breast Cancer): Completed the Phase II portion of the integrated Phase II/III trial in October 2024.
- IMP761 (Autoimmune): First-in-human Phase I trial initiated in August 2024.
- Liquidity Outlook: Management anticipates that current cash and cash equivalents (A$181.8 million including term deposits) will be sufficient to fund operations at least until the end of calendar year 2026.
- Strategic Partnerships: Continued reliance on collaborations with major pharmaceutical companies (MSD, Novartis, EOC Pharma) to share development costs and risks.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, patient enrollment challenges, and the need for additional capital if development costs exceed current forecasts.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the A$181.8 million cash position against the projected burn rate for the upcoming Phase III TACTI-004 trial and other ongoing programs.
- Collaboration Terms: Review the specific financial terms and milestone obligations of the new TACTI-004 collaboration with MSD, particularly regarding funding responsibilities and data rights.
- Clinical Data Validation: Scrutinize the independent review of the TACTI-003 Phase IIb data (35.5% ORR in PD-L1 negative HNSCC) to assess the likelihood of regulatory support for a Phase III trial in this indication.
- Grant Dependency: Assess the sustainability of the A$3.7 million in grant income, which offsets a significant portion of operating expenses, and the eligibility criteria for future R&D tax incentives in Australia and France.
- Convertible Notes: Note the remaining A$0.96 million convertible note liability (6.25% of original balance) maturing in August 2025, which can be converted into shares.